{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:00:47Z","timestamp":1793660447004,"version":"4.5.1"},"reference-count":114,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vaccine.2020.08.050","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T01:39:52Z","timestamp":1602898792000},"page":"3067-3080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["The Brighton Collaboration standardized template for collection of key information for risk\/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform"],"prefix":"10.1016","volume":"39","author":[{"given":"Ariane","family":"Volkmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lise","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Weidenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Condit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-5189","authenticated-orcid":false,"given":"Emily R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-8367","authenticated-orcid":false,"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2020.08.050_b0005","first-page":"397","article-title":"Smallpox: emergence, global spread, and eradication","volume":"15","author":"Fenner","year":"1993","journal-title":"Hist Philos Life Sci"},{"issue":"32","key":"10.1016\/j.vaccine.2020.08.050_b0010","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.vaccine.2004.10.052","article-title":"Reactions to small pox vaccine in naive and previously-vaccinated individuals","volume":"23","author":"Auckland","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2020.08.050_b0020","first-page":"479","article-title":"Comparative experimental works on cow pox virus vaccines","volume":"138","author":"Herrlich","year":"1954","journal-title":"Arch Hyg Bakteriol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0025","first-page":"24","article-title":"Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol Orig"},{"key":"10.1016\/j.vaccine.2020.08.050_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"issue":"35","key":"10.1016\/j.vaccine.2020.08.050_b0035","first-page":"1149","article-title":"Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (\u201cMVA virus\u201d)","volume":"113","author":"Stickl","year":"1971","journal-title":"Munch Med Wochenschr"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.050_b0040","first-page":"253","article-title":"Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA","volume":"107","author":"Mahnel","year":"1994","journal-title":"Berl Munch Tierarztl Wochenschr"},{"issue":"7","key":"10.1016\/j.vaccine.2020.08.050_b0045","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"issue":"52","key":"10.1016\/j.vaccine.2020.08.050_b0050","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2020.08.050_b0055","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2020.08.050_b0060","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1128\/JVI.00756-10","article-title":"Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice","volume":"84","author":"Meisinger-Henschel","year":"2010","journal-title":"J Virol"},{"issue":"39","key":"10.1016\/j.vaccine.2020.08.050_b0065","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA vaccines: dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2020.08.050_b0075","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2020.08.050_b0080","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1099\/vir.0.83156-0","article-title":"Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara","volume":"88","author":"Meisinger-Henschel","year":"2007","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0090","first-page":"13","article-title":"Poxvirus-based vectors as vaccine candidates","volume":"10","author":"Tartaglia","year":"1990","journal-title":"Crit Rev Immunol"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2020.08.050_b0095","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0147-9571(03)00019-5","article-title":"Poxviruses as vaccine vectors","volume":"26","author":"Pastoret","year":"2003","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2020.08.050_b0100","first-page":"71","article-title":"Generation of Recombinant Vaccinia Viruses","volume":"117","author":"Wyatt","year":"2017","journal-title":"Curr Protoc Mol Biol"},{"issue":"7","key":"10.1016\/j.vaccine.2020.08.050_b0105","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1128\/jvi.68.7.4109-4116.1994","article-title":"Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant","volume":"68","author":"Sutter","year":"1994","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jviromet.2010.11.003","article-title":"Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection","volume":"171","author":"Wong","year":"2011","journal-title":"J Virol Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/aid.2007.0205","article-title":"Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C","volume":"24","author":"Burgers","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0120","first-page":"131","article-title":"Generation of recombinant Vaccinia viruses","volume":"89","author":"Wyatt","year":"2017","journal-title":"Curr Protoc Protein Sci"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0125","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/jvi.64.5.2448-2451.1990","article-title":"Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus","volume":"64","author":"Earl","year":"1990","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188453","article-title":"Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments","volume":"13","author":"Noyce","year":"2018","journal-title":"PLoS ONE"},{"issue":"6354","key":"10.1016\/j.vaccine.2020.08.050_b0135","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/354520a0","article-title":"Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine","volume":"354","author":"Brochier","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.08.050_b0140","first-page":"173","article-title":"Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control","volume":"119","author":"Rupprecht","year":"2004","journal-title":"Dev Biol (Basel)"},{"issue":"30","key":"10.1016\/j.vaccine.2020.08.050_b0145","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1016\/j.vaccine.2006.11.066","article-title":"Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform","volume":"25","author":"Poulet","year":"2007","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2020.08.050_b0150","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus Type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2020.08.050_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195897","article-title":"Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial","volume":"13","author":"Overton","year":"2018","journal-title":"PLoS ONE"},{"issue":"20","key":"10.1016\/j.vaccine.2020.08.050_b0160","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.050_b0165","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.vaccine.2020.01.055","article-title":"Safety and immunogenicity of novel modified vaccinia ankara-vectored RSV vaccine: a randomized phase I clinical trial","volume":"38","author":"Samy","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135965350501000212","article-title":"Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption","volume":"10","author":"Harrer","year":"2005","journal-title":"Antivir Ther"},{"issue":"22","key":"10.1016\/j.vaccine.2020.08.050_b0175","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.1158\/1078-0432.CCR-17-1087","article-title":"Phase I study of a Poxviral TRICOM-based vaccine directed against the transcription factor Brachyury","volume":"23","author":"Heery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0264-410X(03)00538-3","article-title":"Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals","volume":"22","author":"Cosma","year":"2003","journal-title":"Vaccine"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2020.08.050_b0185","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0190","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.biologicals.2009.09.007","article-title":"A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines","volume":"38","author":"Zhang","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2020.08.050_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.meegid.2013.10.014","article-title":"Poxviruses and the evolution of host range and virulence","volume":"21","author":"Haller","year":"2014","journal-title":"Infect Genet Evol"},{"issue":"23","key":"10.1016\/j.vaccine.2020.08.050_b0200","doi-asserted-by":"crossref","first-page":"11909","DOI":"10.1128\/JVI.01833-15","article-title":"Genomic analysis, phenotype, and virulence of the historical brazilian smallpox vaccine strain IOC: implications for the origins and evolutionary relationships of Vaccinia virus","volume":"89","author":"Medaglia","year":"2015","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/viro.2000.0603","article-title":"An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine","volume":"277","author":"Damaso","year":"2000","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2020.08.050_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/v9110340","article-title":"Vaccinia virus natural infections in Brazil: the good, the bad, and the ugly","volume":"9","author":"Oliveira","year":"2017","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.050_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/v10030120","article-title":"Bovine Vaccinia: insights into the disease in cattle","volume":"10","author":"Matos","year":"2018","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0220","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1086\/377236","article-title":"Transmission of vaccinia virus and rationale for measures for prevention","volume":"37","author":"Lane","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/mr.55.1.80-122.1991","article-title":"Poxvirus pathogenesis","volume":"55","author":"Buller","year":"1991","journal-title":"Microbiol Rev"},{"issue":"9","key":"10.1016\/j.vaccine.2020.08.050_b0230","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a010199","article-title":"Poxvirus DNA replication","volume":"5","author":"Moss","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4 Suppl","key":"10.1016\/j.vaccine.2020.08.050_b0235","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1586\/14760584.3.4.S89","article-title":"MVA as a vector for vaccines against HIV-1","volume":"3","author":"Im","year":"2004","journal-title":"Expert Rev Vaccines"},{"issue":"16","key":"10.1016\/j.vaccine.2020.08.050_b0240","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2012.02.016","article-title":"Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination","volume":"30","author":"Verheust","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2020.08.050_b0245","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/156652321306140103221941","article-title":"Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors","volume":"13","author":"Goossens","year":"2013","journal-title":"Curr Gene Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2020.08.050_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/v9110318","article-title":"Hazard characterization of modified vaccinia virus ankara vector: what are the knowledge gaps?","volume":"9","author":"Okeke","year":"2017","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2020.08.050_b0255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/j.1326-5377.1977.tb114544.x","article-title":"Adverse reactions after smallpox vaccination","volume":"2","author":"Feery","year":"1977","journal-title":"Med J Aust"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2020.08.050_b0260","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1086\/524380","article-title":"Economics of cardiac adverse events after smallpox vaccination: lessons from the 2003 US Vaccination Program","volume":"46","author":"Ortega-Sanchez","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.050_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118283","article-title":"A prospective study of the incidence of myocarditis\/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination","volume":"10","author":"Engler","year":"2015","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2020.08.050_b0270","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM198703123161106","article-title":"Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease","volume":"316","author":"Redfield","year":"1987","journal-title":"N Engl J Med"},{"issue":"RR-02","key":"10.1016\/j.vaccine.2020.08.050_b0275","first-page":"1","article-title":"Clinical guidance for smallpox vaccine use in a postevent vaccination program","volume":"64","author":"Petersen","year":"2015","journal-title":"MMWR Recomm Rep"},{"issue":"22","key":"10.1016\/j.vaccine.2020.08.050_b0280","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":"Complications of smallpox vaccination, 1968","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.050_b0285","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1542\/peds.55.3.342","article-title":"Smallpox vaccination reactions, prophylaxis, and therapy of complications","volume":"55","author":"Goldstein","year":"1975","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.08.050_b0290","unstructured":"ACAM2000\u2122 Prescribing Information (March 2018); 2018."},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0295","first-page":"889","article-title":"Smallpox vaccine: contraindications, administration, and adverse reactions","volume":"68","author":"Maurer","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2020.08.050_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcdb.2016.07.015","article-title":"Membrane fusion during poxvirus entry","author":"Moss","year":"2016","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: targets of protective immunity","volume":"239","author":"Moss","year":"2011","journal-title":"Immunol Rev"},{"issue":"RR-4","key":"10.1016\/j.vaccine.2020.08.050_b0310","first-page":"1","article-title":"Centers for Disease C, Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians","volume":"52","author":"Cono","year":"2003","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2020.08.050_b0315","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6510a2","article-title":"Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015","volume":"65","author":"Petersen","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.050_b0320","first-page":"2","article-title":"Spread of vaccinia virus through shaving during military training, Joint Base San Antonio-Lackland, TX, June 2014","volume":"21","author":"Webber","year":"2014","journal-title":"MSMR"},{"issue":"7","key":"10.1016\/j.vaccine.2020.08.050_b0325","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1073\/pnas.1921098117","article-title":"Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells","volume":"117","author":"Peng","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0330","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0335","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv040","article-title":"Safety and immunogenicity of modified vaccinia ankara-bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical Phase II Trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.08.050_b0340","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","article-title":"A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS","volume":"38","author":"Overton","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.050_b0345","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-0183","article-title":"A Phase 1 dose escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules","author":"Gatti-Mays","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2020.08.050_b0350","article-title":"Phase I trial of a modified vaccinia ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors","author":"Collins","year":"2019","journal-title":"Oncologist"},{"issue":"43","key":"10.1016\/j.vaccine.2020.08.050_b0355","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis","volume":"32","author":"von Sonnenburg","year":"2014","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2020.08.050_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138348","article-title":"A multicenter, open-label, controlled Phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18\u201340 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2020.08.050_b0365","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.050_b0370","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fimmu.2017.00149","article-title":"A comparative Phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein\/adjuvant HIV vaccines in two immunization regimes","volume":"8","author":"Joseph","year":"2017","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2020.08.050_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179597","article-title":"Immunogenicity of a novel Clade B HIV-1 vaccine combination: results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults","volume":"12","author":"Buchbinder","year":"2017","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2020.08.050_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186602","article-title":"Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization","volume":"12","author":"Guardo","year":"2017","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.vaccine.2020.08.050_b0385","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/infdis\/jix456","article-title":"Safety and immunogenicity of PENNVAX-G DNA prime administered by biojector 2000 or CELLECTRA electroporation device with modified Vaccinia Ankara-CMDR boost","volume":"216","author":"Ake","year":"2017","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.08.050_b0390","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1128\/CVI.00717-15","article-title":"Subtype C gp140 vaccine boosts immune responses primed by the South African AIDS vaccine initiative DNA-C2 and MVA-C HIV vaccines after more than a 2-Year Gap","volume":"23","author":"Gray","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.08.050_b0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157335","article-title":"A randomized, double-blind, placebo-controlled Phase II trial investigating the safety and immunogenicity of modified Vaccinia Ankara smallpox vaccine (MVA-BN(R)) in 56\u201380-year-old subjects","volume":"11","author":"Greenberg","year":"2016","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155702","article-title":"Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: a Phase I trial","volume":"11","author":"Joachim","year":"2016","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2020.08.050_b0405","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2020.08.050_b0410","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0415","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2020.08.050_b0420","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2020.08.050_b0425","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5x10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1x10(8) TCID50) in healthy vaccinia-naive individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.vaccine.2020.08.050_b0430","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.08.050_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122653","article-title":"Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population","volume":"10","author":"Zitzmann-Roth","year":"2015","journal-title":"PLoS ONE"},{"issue":"13","key":"10.1016\/j.vaccine.2020.08.050_b0440","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.vaccine.2017.02.032","article-title":"Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: a randomized clinical non-inferiority trial","volume":"35","author":"Jackson","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0445","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virol.2010.04.015","article-title":"Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses","volume":"403","author":"Manuel","year":"2010","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0450","first-page":"766","article-title":"Construction and biological characteristic for the recombinant modified vaccinia virus ankara co-expressing modified GP5 and M protein of porcine reproductive and respiratory syndrome virus","volume":"24","author":"Zheng","year":"2008","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"issue":"21","key":"10.1016\/j.vaccine.2020.08.050_b0455","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1016\/j.vaccine.2005.08.037","article-title":"Genetic stability of recombinant MVA-BN","volume":"24","author":"Timm","year":"2006","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2020.08.050_b0460","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0465","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a Phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0470","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0475","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/21645515.2017.1264755","article-title":"A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks","volume":"13","author":"Shukarev","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.050_b0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2020.08.050_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196546","article-title":"Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.08.050_b0490","article-title":"Broad antibody and cellular immune response from a Phase 2 clinical trial with a novel multivalent poxvirus based RSV vaccine","author":"Jordan","year":"2020","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.050_b0495","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1128\/JVI.78.8.3965-3976.2004","article-title":"Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus","volume":"78","author":"Wang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.050_b0500","first-page":"397","article-title":"Environmental resistance, disinfection, and sterilization of poxviruses","author":"Rheinbaben","year":"2007"},{"issue":"31","key":"10.1016\/j.vaccine.2020.08.050_b0505","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.vaccine.2020.08.050_b0510","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0515","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI33940","article-title":"Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection","volume":"118","author":"Samuelsson","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.08.050_b0520","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fimmu.2018.01756","article-title":"Immunogenicity and protection after vaccination with a modified Vaccinia virus Ankara-vectored yellow fever vaccine in the hamster model","volume":"9","author":"Julander","year":"2018","journal-title":"Front Immunol"},{"issue":"34","key":"10.1016\/j.vaccine.2020.08.050_b0525","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1016\/j.vaccine.2018.06.064","article-title":"Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses","volume":"36","author":"Hu","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.050_b0530","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00262-016-1816-7","article-title":"Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells","volume":"65","author":"Foy","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.20.1.21171","article-title":"Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects","volume":"20","author":"Hancock","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"10","key":"10.1016\/j.vaccine.2020.08.050_b0540","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.vaccine.2010.12.104","article-title":"A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects","volume":"29","author":"Keefer","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.08.050_b0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5\u201317 months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.08.050_b0550","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-018-0084-2","article-title":"Safety and efficacy of novel malaria vaccine regimens of RTS, S\/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP","volume":"3","author":"Rampling","year":"2018","journal-title":"npj Vaccines"},{"issue":"30","key":"10.1016\/j.vaccine.2020.08.050_b0555","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.050_b0560","unstructured":"JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) Prescribing Information. 09\/2019."},{"key":"10.1016\/j.vaccine.2020.08.050_b0565","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.antiviral.2018.11.004","article-title":"Vaccinating against monkeypox in the Democratic Republic of the Congo","volume":"162","author":"Petersen","year":"2019","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.050_b0570","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0091-7435(74)90066-8","article-title":"Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine \u201cMVA\u201d","volume":"3","author":"Stickl","year":"1974","journal-title":"Prev Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:58:59Z","timestamp":1759402739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20310914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":114,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0264410X20310914"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Brighton Collaboration standardized template for collection of key information for risk\/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}